Literature DB >> 19856098

Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.

Ke-Da Yu1, Lei Fan, Gen-Hong Di, Wen-Tao Yuan, Ying Zheng, Wei Huang, Ao-Xiang Chen, Chen Yang, Jiong Wu, Zhen-Zhou Shen, Zhi-Ming Shao.   

Abstract

Mu class of Glutathione-S-transferase (GSTM) genes arrange in a tandem on chromosome 1p13.3. The relationship between genetic variants in the GSTM1-5 gene cluster and breast cancer is still ambiguous. In the present study, 17 tagging single-nucleotide polymorphisms (SNPs) covering the GSTMs cluster were originally selected and 11 validated SNPs were used for genotyping 921 cases and 711 controls. The association analyses were performed according to the absence or presence of GSTM1. In the GSTM1-/- group, the allele frequency of one SNP in GSTM3 was significantly different between cases and controls (P = 2.0 x 10(-4), corrected P = 0.001), with odds ratio of 1.75 (95% confidence interval, 1.26-2.44). The observed association in the GSTM1-/- group was successfully replicated in an independent population set (familial/early-onset breast cancer cases, n = 267; community-based controls, n = 667). The combined P values were robust (10(-6)) and the false positive report probability (FPRP) values were low. In contrast, no susceptibility allele/haplotype was identified when the GSTM1 gene was present. Based on epidemiological observations, we further identified two genetic variants in the GSTM3 locus accounting for differential expression of GSTM3 in normal breast tissues by such means as altering binding of RNA-pol-II. Protective genotypes were correlated with higher GSTM3 expression levels. In conclusion, SNPs/haplotypes in the GSTM3 gene within the GSTMs gene cluster are likely to contribute to breast cancer risk when the GSTM1 is absent. We infer that GSTM3 catalyzing ability in normal breast tissue might protect against breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856098     DOI: 10.1007/s10549-009-0585-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

2.  Defining a relationship between dietary fatty acids and the cytochrome P450 system in a mouse model of fatty liver disease.

Authors:  Monika Gonzalez; Whitney Sealls; Elliot D Jesch; M Julia Brosnan; Istvan Ladunga; Xinxin Ding; Paul N Black; Concetta C DiRusso
Journal:  Physiol Genomics       Date:  2010-11-23       Impact factor: 3.107

3.  Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

Authors:  Hung-Lung Ke; Jie Lin; Yuanqing Ye; Wen-Jeng Wu; Hui-Hui Lin; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Ann Surg Oncol       Date:  2015-04-08       Impact factor: 5.344

4.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Authors:  Manoj Kumar Kashyap; H C Harsha; Santosh Renuse; Harsh Pawar; Nandini A Sahasrabuddhe; Min-Sik Kim; Arivusudar Marimuthu; Shivakumar Keerthikumar; Babylakshmi Muthusamy; Kumaran Kandasamy; Yashwanth Subbannayya; Thottethodi Subrahmanya Keshava Prasad; Riaz Mahmood; Raghothama Chaerkady; Stephen J Meltzer; Rekha V Kumar; Anil K Rustgi; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

5.  MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.

Authors:  Xiaofan Zhang; Hushan Yang; J Jack Lee; Edward Kim; Scott M Lippman; Fadlo R Khuri; Margaret R Spitz; Reuben Lotan; Waun K Hong; Xifeng Wu
Journal:  Carcinogenesis       Date:  2010-09-05       Impact factor: 4.944

6.  Association of glutathione S-transferase T1, M1 and P1 polymorphisms in the breast cancer risk: a meta-analysis in Asian population.

Authors:  Jianqiu Tang; Qiaoxia Zhou; Fen Zhao; Fulin Wei; Jian Bai; Yuping Xie; Ying Huang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.

Authors:  X Tan; Y Wang; Y Han; W Chang; T Su; J Hou; D Xu; Y Yu; W Ma; T C Thompson; G Cao
Journal:  Br J Cancer       Date:  2013-10-24       Impact factor: 7.640

8.  Anti-Cancer Effects and Tumor Marker Role of Glutathione S-Transferase Mu 5 in Human Bladder Cancer.

Authors:  Yeong-Chin Jou; Shou-Chieh Wang; Yuan-Chang Dia; Shou-Tsung Wang; Min-Hua Yu; Hsin-Yi Yang; Lei-Chin Chen; Cheng-Huang Shen; Yi-Wen Liu
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

9.  A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse.

Authors:  Dan-Na Chen; Chuan-Gui Song; Ke-Da Yu; Yi-Zhou Jiang; Fu-Gui Ye; Zhi-Ming Shao
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

10.  GSTM3 reverses the resistance of hepatoma cells to radiation by regulating the expression of cell cycle/apoptosis-related molecules.

Authors:  Ying Sun; Yu Wang; Yufeng Yin; Xianghua Chen; Zhijun Sun
Journal:  Oncol Lett       Date:  2014-07-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.